ICOS and non-small cell lung carcinoma: Subsequent analysis of immunomodulators with prognosis of NSCLC patients using Kaplan–Meier plotter displayed that high expression of four immunostimulators (TMEM173, HR = 0.58, p = 9.6e−06; IL6R, HR = 0.36, p = 5.0e−15; ICOS, HR = 0.49, p = 5.4e−09; and ENTPD1, HR = 0.62, p = 1.6e−04) and one immunoinhibitor (CTLA4, HR = 0.57, p = 5.6e−06) were related to good prognosis of LUAD patients (Fig. 4G).